{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:52:12Z","timestamp":1791528732110,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019518","name":"Eli Lilly Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009881","name":"Breakthrough T1D Canada","doi-asserted-by":"publisher","award":["3-SRA-2024-1523-M-N"],"award-info":[{"award-number":["3-SRA-2024-1523-M-N"]}],"id":[{"id":"10.13039\/100009881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008985","name":"Diab\u00e8te Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008985","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011848","name":"Novo Nordisk Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021570","name":"Strategy for Patient-Oriented Research","doi-asserted-by":"publisher","award":["JT1-157204"],"award-info":[{"award-number":["JT1-157204"]}],"id":[{"id":"10.13039\/100021570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jdiacomp.2026.109417","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:56:11Z","timestamp":1789602971000},"page":"109417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes phenotyping, insulin management and complications in latent autoimmune diabetes in adults (LADA): patient-reported outcomes of the Canadian BETTER registry"],"prefix":"10.1016","volume":"40","author":[{"given":"Maya","family":"Nehme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishara Samuna","family":"Baseme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Messier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Dawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Brazeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109417_bb0005","author":"World Health Organization"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0010","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s00125-005-1960-7","article-title":"Latent autoimmune diabetes in adults (LADA) should be less latent","volume":"48","author":"Fourlanos","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0015","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0020","article-title":"LADA 30th anniversary: a growing form of diabetes with persistent unresolved questions","volume":"40","author":"Lee","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0025","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/dbi20-0017","article-title":"Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/dmrr.2411","article-title":"Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain","volume":"29","author":"Mollo","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.102986","article-title":"Classification of type 1 diabetes: a pathogenic and treatment-based classification","volume":"18","author":"Patel","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0040","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3928","article-title":"Decreased quality of life and treatment satisfaction in patients with latent autoimmune diabetes of the adult","volume":"5","author":"Granado-Casas","year":"2017","journal-title":"PeerJ"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3803\/EnM.2018.33.2.147","article-title":"Latent autoimmune diabetes in adults: current status and new horizons","volume":"33","author":"Pozzilli","year":"2018","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-15-1","article-title":"Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9","volume":"15","author":"Hernandez","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0055","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jcjd.2022.05.010","article-title":"Self-reported severe and nonsevere hypoglycemia in type 1 diabetes: population surveillance through the BETTER Patient Engagement Registry: development and baseline characteristics","volume":"46","author":"Brazeau","year":"2022","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0065","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0070","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0075","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2337\/dc21-1331","article-title":"The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes","volume":"44","author":"Lachin","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0080","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up","volume":"39","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00390-6","article-title":"Adult-onset autoimmune diabetes","volume":"8","author":"Buzzetti","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0090","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1530\/EJE-14-0342","article-title":"High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)","volume":"171","author":"Zampetti","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13098-024-01479-6","article-title":"Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM?","volume":"16","author":"Zhou","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00125-005-1690-x","article-title":"Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70)","volume":"48","author":"Davis","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155643","article-title":"Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan","volume":"11","author":"Yasui","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-10-0901","article-title":"\u03b2-Cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up","volume":"164","author":"Thunander","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0120","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/dom.15469","article-title":"Saxagliptin\/dapagliflozin is non-inferior to insulin glargine in terms of \u03b2-cell function in subjects with latent autoimmune diabetes in adults: a 12-month, randomized, comparator-controlled pilot study","volume":"26","author":"Maddaloni","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1590\/S0004-27302007000100009","article-title":"Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization","volume":"51","author":"Ros\u00e1rio","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0130","first-page":"1723","article-title":"Efficacy of regimens in the treatment of latent autoimmune diabetes in adults: a network meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0135","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jdi.13814","article-title":"Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: a systematic review and meta-analysis","volume":"13","author":"Lin","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0140","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S2213-8587(20)30003-6","article-title":"Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)","volume":"8","author":"Maddaloni","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0145","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/dom.13788","article-title":"Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85)","volume":"21","author":"Maddaloni","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/dc07-1308","article-title":"Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults","volume":"31","author":"Brophy","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0155","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.2337\/diacare.24.8.1460","article-title":"Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention","volume":"24","author":"Pozzilli","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0160","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(97)03062-6","article-title":"UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes","volume":"350","author":"Turner","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0165","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc21-0770","article-title":"Adult-onset type 1 diabetes: current understanding and challenges","volume":"44","author":"Leslie","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0170","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annepidem.2007.03.013","article-title":"Participation rates in epidemiologic studies","volume":"17","author":"Galea","year":"2007","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14455","article-title":"Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: a cross-sectional study","volume":"38","author":"Maddaloni","year":"2021","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0180","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2337\/dc23-0739","article-title":"All-cause mortality and cardiovascular and microvascular diseases in latent autoimmune diabetes in adults","volume":"46","author":"Wei","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.maturitas.2020.04.014","article-title":"Adult-onset autoimmune diabetes in 2020: an update","volume":"137","author":"Maddaloni","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0190","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0195","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/j.jcjd.2017.10.025","article-title":"Screening for the presence of cardiovascular disease","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0200","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2337\/dc23-1765","article-title":"Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey","volume":"47","author":"Sherr","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0205","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2337\/dc18-1796","article-title":"Diabetes-related complications and mortality in patients with young-onset latent autoimmune diabetes: a 14-year analysis of the prospective Hong Kong Diabetes Register","volume":"42","author":"Luk","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0210","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s12020-024-03901-5","article-title":"Factors associated with Glycemia Risk Index in a cohort of patients with type 1 Diabetes Mellitus and Latent Autoimmune Diabetes In Adults (LADA)","volume":"86","author":"Herranz-Antol\u00edn","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.jdiacomp.2026.109417_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000983","article-title":"Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II","volume":"8","author":"Davis","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2026.109417_bb9000","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/dom.13237","article-title":"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials","volume":"20","author":"Pozzilli","year":"2018","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:47:11Z","timestamp":1791528431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872726001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1056872726001625"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109417","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes phenotyping, insulin management and complications in latent autoimmune diabetes in adults (LADA): patient-reported outcomes of the Canadian BETTER registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109417"}}